In the recent report by Peter Wennink, biotech has been recognised as one of the most promising growth engines of the Netherlands’ future economy, next to the direct benefits to patients and the clinical research community. To fully utilise this potential, it is very important to consider what is needed to fuel a full end-to-end  life science & health ecosystem, from early innovation to access for patients in daily practice.

The session Bridging the Gap between Innovation and Access will address the  consequences of a potential gap between healthcare innovation, clinical trials and access to innovation for patients, focusing specifically on the situation in the Netherlands. The session aims to foster dialogue and actionable insights for all stakeholders who are striving to overcome the barriers between pioneering innovations and their adoption in clinical trials and daily clinical practice, ultimately serving the need of patients. 

Keynote Introduction: Current Status in the Netherlands

Hans Schikan, renowned for his expertise in healthcare innovation, will deliver the keynote introduction. He will provide an overview of the current Dutch end-to-end ecosystem for healthcare innovations, and will focus on the gap in the Netherlands, highlighting key factors that impede the effective translation of novel health technologies and treatments into clinical trial opportunities and accessible options for patients and clinicians.

Panel Discussion: Consequences for Clinical Research

• Gain an informed perspective on the gap between innovation, clinical trials and access in the Netherlands
• Hear insights from experts representing clinical research, hospital management, and research funding organizations
• Understand the impact of the gap on clinical research and healthcare delivery, and identify opportunities for collaboration and practical solutions to bridge the gap